Applications

ABCDEFGHIJKLM
NOPQRSTUVWXYZALL

Monitoring Cardiotoxicity

Measurements of cell health are a fundamental component of any disease research and drug development effort.

Learn More
Print
Description Available Resources

Monitoring Cardiotoxicity

Discovery, Toxicity

Measurements of cell health are a fundamental component of any disease research and drug development effort. Cell health endpoints represent various biological processes including cell morphology, viability, cytotoxicity, apoptosis, and mitochondrial integrity. In drug development, researchers interrogate these endpoints as part of discovery screening efforts as well as toxicity studies. CDI’s cardiomyocytes have been utilized to measure various cardiac cell health endpoints using platforms including:

Plate-based Fluorescent and Luminescent Assays:

  1. Robers M and Jarecki B. (2014) Efficiently Build Relevant In Vitro Models Using Human Stem Cell-derived Tissue Cells, High Performance Transfection and Novel Multiplexed Reporter Techniques. Promega/Cellular Dynamics Webinar.
  2. Evans NJ, Kirkland TA, et al. (2012) A Multiplexed, Bioluminescent HDAC Assay for Determining Target-specific, Anti-cancer Potency. Poster Presentation, AACR.
  3. Reynolds JG, Geretti E, et al. (2012) HER2-targeted Liposomal Doxorubicin Displays Enhanced Anti-tumorigenic Effects without Associated Cardiotoxicity. Toxicol Appl Pharmacol 262(1):1-10.

Metabolism Analysis:

  1. Performing Bioenergetic Analysis: X96 Extracellular Flux Analyzer. Cellular Dynamics Application Protocol.
  2. Rana P, Anson BD, et al. (2012) Characterization of Human-induced Pluripotent Stem Cell-derived Cardiomyocytes: Bioenergetics and Utilization in Safety Screening. Toxicol Sci 130(1):117-31.

High Content Analysis:

  1. Sirenko O, Cromwell EF, et al. (2013) Assessment of Beating Parameters in Human Induced Pluripotent Stem Cells Enables Quantitative In Vitro Screening for Cardiotoxicity. Toxicol Appl Pharmacol 273(3):500-07.
  2. Mioulane M, Foldes G, et al. (2012) Development of High Content Imaging Methods for Cell Death Detection in Human Pluripotent Stem Cell-derived Cardiomyocytes. J Cardiovasc Trans Res 5(5):593-604.
  3. Schweikart K, Guo L, et al. (2013) The Effects of Jaspamide on Human Cardiomyocyte Function and Cardiac Ion Channel Activity. Toxicol In Vitro 27(2):745-51.

Impedance Measurement:

  1. Talbert DR, Doherty KR, et al. (2014) A Multi-parameter In Vitro Screen in Human Stem Cell-derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity. Toxicol Sci 143(1):147-55.
  2. Doherty K, Wappel R, et al. (2013) Multi-parameter In Vitro Toxicity Testing of Crizotinib, Sunitinib, Erlotinib, and Nilotinib in Human Cardiomyocytes. Toxicol Appl Pharmacol 272(1):245-55.
  3. Cameron BJ, Gerry AB, et al. (2013) Identification of a Titin-derived HLA-A1-presented Peptide as a Cross-reactive Target for Engineered MAGE A3-directed T Cells. Sci Transl Med 5(197):197ra103.
  4. Cohen JD, Babiarz JE, et al. (2011) Use of Human Stem Cell-derived Cardiomyocytes to Examine Sunitinib Mediated Cardiotoxicity and Electrophysiological Alterations. Toxicol Appl Pharmacol 257(1):74-83.
  5. Schweikart K, Guo L, et al. (2013) The Effects of Jaspamide on Human Cardiomyocyte Function and Cardiac Ion Channel Activity. Toxicol In Vitro 27(2):745-51.

Measuring Cardiomyocyte Electrophysiology

The dysregulation of ion channel function and electrical signaling is a key cause of congenital, environmental, and drug-induced cardiac dysfunction.

Learn More
Print
Description Available Resources

Measuring Cardiomyocyte Electrophysiology

Discovery, Toxicity

The dysregulation of ion channel function and electrical signaling is a key cause of congenital, environmental, and drug-induced cardiac dysfunction. CDI’s cardiomyocytes recapitulate in vivo cardiac function and have demonstrated utility in monitoring electrical activity at molecular, cellular, and organotypic levels using platforms including:

Manual Patch Clamp:

  1. Measuring Cardiac Electrical Activity: Manual Perforated Patch Clamp. Cellular Dynamics Application Protocol.
  2. Gibson JK, Yue Y, et al. (2014) Human Stem Cell-derived Cardiomyocytes Detect Drug-mediated Changes in Action Potentials and Ion Currents. J Pharmacol Toxicol Methods 70(3):255-67.
  3. Jehle J, Ficker E, et al. (2013) Mechanisms of Zolpidem-induced Long QT Ayndrome: Acute Inhibition of Recombinant hERG K+ Channels and Action Potential Prolongation in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells. Br J Pharmacol 168(5):1215-29.
  4. Ivashchenko CY, Pipes GC, et al. (2013) Human-induced Pluripotent Stem Cell-derived Cardiomyocytes Exhibit Temporal Changes in Phenotype. Am J Physiol Heart Circ Physiol 305(6):H913-22.
  5. Wei H, Zhang G, et al. (2012) Hydrogen Sulfide Suppresses Outward Rectifier Potassium Currents in Human Pluripotent Stem Cell-derived Cardiomyocytes. PloS One 7(11):e50641.
  6. Ma J, Guo L, et al. (2011) High Purity Human-induced Pluripotent Stem Cell-derived Cardiomyocytes: Electrophysiological Properties of Action Potentials and Ionic Currents. Am J Physiol Heart Circ Physiol 301(5):H2006-H2017.
  7. Fine M, Lu F, et al. (2013) Human Induced Pluripotent Stem Cell-derived Cardiomyocytes for Studies of Cardiac Ion Transporters. Am J Physiol Cell Physiol 305(5):C481-91.

Automated Patch Clamp:

  1. Ma J, Guo L, et al. (2011) High Purity Human-induced Pluripotent Stem Cell-derived Cardiomyocytes: Electrophysiological Properties of Action Potentials and Ionic Currents. Am J Physiol Heart Circ Physiol 301(5):H2006-H2017.
  2. Cohen JD, Babiarz JE, et al. (2011) Use of Human Stem Cell-derived Cardiomyocytes to Examine Sunitinib Mediated Cardiotoxicity and Electrophysiological Alterations. Toxicol Appl Pharmacol 257(1):74-83.
  3. Schroder R, Christensen MT, et al. (2013) Exploring Stem Cell-derived Cardiomyocytes with Automated Patch Clamp Techniques. Poster Presentation, Sophion User Meeting.

MEA:

  1. Measuring Cardiac Electrical Activity: Field Potential Detection on the Maestro Multielectrode Array. Cellular Dynamics Application Protocol. [iCell Cardiomyocytes]
  2. Measuring Cardiac Electrical Activity: Field Potential Detection on the Maestro Multielectrode Array. Cellular Dynamics Application Protocol. [iCell Cardiomyocytes2]
  3. Harris K, Aylott M, et al. (2013) Comparison of Electrophysiological Data from Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (hiPSC-CMs) to Functional Pre-clinical Safety Assays. Toxicol Sci 134(2):412-26.
  4. Guo L, Coyle L, et al. (2013) Refining the Human iPSC-cardiomyocyte Arrhythmic Risk Assessment Model. Toxicol Sci 136(2):581-94.

Voltage Sensitive Dyes:

  1. Lee P, Kloss M, et al. (2012) Simultaneous Voltage and Calcium Mapping of Genetically Purified Human Induced Pluripotent Stem Cell-derived Cardiac Myocyte Monolayers. Circ Res 110(12):1556-63.
  2. Zamora V, Hortigon‐Vinagre MP, et al. (2014) Rapid Intensity Modulation of a Single Light Source Allows Excitation of Voltage Sensitive Dye and Intermittent Activation of Channel Rhodopsin in hiPSC Derived Cardiomyocytes (hiPSC‐CMs). Poster Presentation, SPS.

 

Measuring Cardiomyocyte Contractility

The modulation of cardiomyocyte contraction (inotropy) is an important phenotypic endpoint for drug discovery, both in the context of intended outcomes and adverse side effects.

Learn More
Print
Description Available Resources

Measuring Cardiomyocyte Contractility

Discovery, Toxicity

The modulation of cardiomyocyte contraction (inotropy) is an important phenotypic endpoint for drug discovery, both in the context of intended outcomes and adverse side effects. CDI’s cardiomyocytes have been used to perform direct measurement of cellular movement or indirect measurement of changes in cell morphology using platforms including:

Measuring Intracellular Signaling in Cardiomyocytes

Various intracellular Ca2+ and phosphorylation-mediated signaling pathways play a central role in translating electrical signals at the cell membrane into physical contractile function.

Learn More
Print
Description Available Resources

Measuring Intracellular Signaling in Cardiomyocytes

Discovery, Toxicity

Various intracellular Ca2+ and phosphorylation-mediated signaling pathways play a central role in translating electrical signals at the cell membrane into physical contractile function. These pathways can be measured in CDI’s cardiomyocytes using platforms including:

Modeling Cardiac Hypertrophy

Cardiac hypertrophy can occur in response to various pathological stimuli and is characterized by cellular changes including reactivation of the fetal gene program, increases in cellular volume...

Learn More
Print
Description Available Resources

Modeling Cardiac Hypertrophy

Discovery, Disease Modeling

Cardiac hypertrophy can occur in response to various pathological stimuli and is characterized by cellular changes including reactivation of the fetal gene program, increases in cellular volume, and reorganization of the cytoskeleton. Using CDI’s cardiomyocytes, researchers can induce the hypertrophic condition in vitro using stimuli, such as endothelin-1, and measured by phenotypic endpoints including:

  • BNP gene expression by qRT-PCR
  • BNP protein expression by flow cytometry
  • BNP protein expression by HCA
  • BNP protein secretion by ELISA

Modeling Hypoxia

Myocardial ischemia is a pathological condition characterized by reduced oxygen supply (hypoxia) that can lead to cell death, arrhythmia, organ injury, and death.

Learn More
Print
Description Available Resources

Modeling Hypoxia

Discovery, Disease Modeling

Myocardial ischemia is a pathological condition characterized by reduced oxygen supply (hypoxia) that can lead to cell death, arrhythmia, organ injury, and death. Ironically, returning hypoxic myocardium to normoxic levels exacerbates the pathology (collectively known as myocardial reperfusion injury). CDI’s cardiomyocytes are amenable to hypoxia induction, measurement of hypoxia-induced functional endpoints, and screening for cardioprotective agents.

Modeling Diabetic Cardiomyopathy

Diabetic cardiomyopathy is a complication of type 2 diabetes that results from lifestyle and genetic conditions.

Learn More
Print
Description Available Resources

Modeling Diabetic Cardiomyopathy

Discovery, Disease Modeling

Diabetic cardiomyopathy is a complication of type 2 diabetes that results from lifestyle and genetic conditions. CDI’s cardiomyocytes have been used to develop environmental and patient-specific in vitro models that recapitulate this complex metabolic condition. These models are employed in a phenotypic screening assay resulting in the identification of candidate protective molecules.

Measuring Hematopoietic Cell Proliferation (CFU/CFC Assays)

The ability to model human hematopoietic cell differentiation is critical for many areas of biomedical research including drug-induced hematopoietic cell toxicity, bone marrow transplant tolerance, cancer immunother

Learn More
Print
Description Available Resources

Measuring Hematopoietic Cell Proliferation (CFU/CFC Assays)

Discovery, Toxicity

The ability to model human hematopoietic cell differentiation is critical for many areas of biomedical research including drug-induced hematopoietic cell toxicity, bone marrow transplant tolerance, cancer immunotherapy, and autoimmune disorders. CDI’s hematopoietic progenitor cells offer access to commercial quantities of highly pure hematopoietic cells, providing reproducible results for these and other research and therapeutic applications.

Measuring Cardiac Progenitor Cell Proliferation and Differentiation

The ability to model human cell and organ developmental pathways is critical to understanding developmental toxicities and disease pathways, and to develop therapeutic strategies for tissue regeneration.

Learn More
Print
Description Available Resources

Measuring Cardiac Progenitor Cell Proliferation and Differentiation

Discovery, Regenerative Medicine, Toxicity

The ability to model human cell and organ developmental pathways is critical to understanding developmental toxicities and disease pathways and to developing therapeutic strategies for tissue regeneration. CDI’s cardiac progenitor cells are multipotent cardiomyocyte precursor cells that exhibit robust and measurable proliferation and differentiation. Assays with these cells are being used in targeted and phenotypic screens to identify therapeutic candidates for cardiac regeneration.

Modeling Hepatitis Infection

Hepatitis infection mediated by HCV and HBV is a common cause of liver disease and failure.

Learn More
Print
Description Available Resources

Modeling Hepatitis Infection

Discovery, Disease Modeling

Hepatitis infection mediated by HCV and HBV is a common cause of liver disease and failure. Developing effective therapies for hepatitis has been limited due to the lack of physiologically relevant human disease models. CDI’s hepatocytes express hepatitis receptors (SR-B1, CD91, occludin, claudin-1), which support uptake and replication of clinically relevant hepatitis virus genotypes. These hepatocytes are being used in large-scale screens for novel therapeutic candidates. CDI offers hepatocytes from multiple donors including one with an IFNL4 function that does not readily clear HCV infection.

Measuring Drug Metabolism

Drug metabolism is a key function of the human liver and is largely accomplished via the activity of P450 cytochromes and other enzymes within hepatocytes.

Learn More
Print
Description Available Resources

Measuring Drug Metabolism

Toxicity

Drug metabolism is a key function of the human liver and is largely accomplished via the activity of P450 cytochromes and other enzymes within hepatocytes. Understanding drug metabolism pathways is critical to defining the availability of therapeutic agents and identifying toxic metabolites. CDI’s hepatocytes exhibit P450 activity that is sustained for over 7 days in culture. In addition, functional P450 induction in response to known inducers has been demonstrated.

  1. P450-Glo Assays. Promega Technical Bulletin.

Monitoring Neurotoxicity

Measurements of cell health are a fundamental component of any disease research and drug development effort.

Learn More
Print
Description Available Resources

Monitoring Neurotoxicity

Discovery, Toxicity

Measurements of cell health are a fundamental component of any disease research and drug development effort. Cell health endpoints represent various biological processes including cell morphology, viability, cytotoxicity, apoptosis, and mitochondrial integrity. In drug development, researchers interrogate these endpoints as part of discovery screening efforts and toxicity studies. CDI’s neurons, dopaneurons, and astrocytes have been utilized to measure various neural cell health endpoints using platforms including:

Monitoring Hepatotoxicity

Unforeseen liver toxicity is a primary mode of clinical failure for drugs in development.

Learn More
Print
Description Available Resources

Monitoring Hepatotoxicity

Toxicity

Unforeseen liver toxicity is a primary mode of clinical failure for drugs in development. The long-term stability of CDI’s hepatocytes in culture affords the opportunity to perform repeat dosing at physiologically relevant concentrations to aid in the identification of drug toxicity. Specific mechanisms of hepatotoxicity, such as cell viability, mitochondrial toxicity, and phospholipidosis, can be measured using platforms including:

  1. Sirenko O, Hesley J, et al. (2014) High-content Assays for Hepatotoxicity Using Induced Pluripotent Stem Cell-derived Cells. Assay Drug Dev Technol 12(1):43-54.
  2. Berger DR, Ware BR, et al. (2014) Enhancing the Functional Maturity of iPSC-derived Human Hepatocytes via Controlled Presentation of Cell-Cell Interactions In Vitro. Hepatology 61(4):1370-81.
  3. Einhorn S, Lu J, et al. (2013) Detection of Xenobiotic-induced Hepatotoxicity in Human iPSC-derived Hepatocytes. Poster Presentation, ISSX.
  4. Lu J, Metushi I, et al. (2013) Investigation of Isoniazid DILI Mechanisms in Human Induced Pluripotent Stem Cell Derived Hepatocytes. Poster Presentation, ISSX.
  5. Einhorn S, Salvagiotto G, et al. (2013) Characterization and Function of iPSC derived Hepatocytes for Use in Toxicity. Poster Presentation, SOT.
  6. Mann DA. (2014) Human Induced Pluripotent Stem Cell-derived Hepatocytes for Toxicology Testing. Exp Opin Drug Metab & Toxicol 11(1):1-5.

Measuring Vasculogenesis

The ability to modulate vasculogenesis has utility in tissue engineering and repair as well as in oncology therapeutics development aimed at targeting angiogenesis.

Learn More
Print
Description Available Resources

Measuring Vasculogenesis

Discovery, Regenerative Medicine

The ability to modulate vasculogenesis has utility in tissue engineering and repair as well as in oncology therapeutics development aimed at targeting angiogenesis. The processes of endothelial cell migration and invasion and vascular sprouting behavior can be measured using CDI’s endothelial cells using platforms including:

  1. Belair DG, Whisler JA, et al. (2014) Human Vascular Tissue Models Formed from Human Induced Pluripotent Stem Cell Derived Endothelial Cells. Stem Cell Rev. [Epub ahead of print]
  2. Belair D, Carlson C, et al. (2014) Label-free, Real-time Analysis of Endothelial Cell Morphogenesis Using iPSC-derived Endothelial Cells. Poster Presentation, AACR.

Measuring Neurite Outgrowth

During development, neurons become assembled into functional networks by growing axons and dendrites that connect synaptically to other neurons.

Learn More
Print
Description Available Resources

Measuring Neurite Outgrowth

Discovery, Toxicity

During development, neurons become assembled into functional networks by growing axons and dendrites that connect synaptically to other neurons. Understanding this process of neurite outgrowth is a major focus of neuroscience research and central to drug discovery efforts in neurodegenerative disease and neurotoxicity studies. CDI’s neurons rapidly form complex cell networks and are an ideal model for assessing neurite outgrowth enhancement, inhibition, and protection with target compounds. These changes can be measured using platforms including:

High Content Analysis:

  1. Assessing Neurite Outgrowth: Quantification with High Content Screening. Cellular Dynamics Application Protocol.
  2. Sherman SP and Bang AG. (2014) High Content Screen for Compounds That Modulate Neurite Outgrowth and Retraction Using Human Induced Pluripotent Stem Cell-derived Neurons. Poster Presentation, ISSCR.
  3. High-content Screening of Neuronal Toxicity Using iPSC-derived Human Neurons. Molecular Devices Application Note.

Plate-based Fluorescence & Luminescence Assays:

  1. Immunofluorescent Labeling. Cellular Dynamics Application Protocol.

Label-free Analysis:

  1. Alcantara S, Garay P, et al. (2014) Development of 96/384-well Kinetic Neurite Outgrowth/Stabilisation Assays in Human iPSC-derived Neurons Using Long Term Live Cell Imaging. Poster Presentation, FENS.

Pageof 2